| abstract |
The present invention provides compounds that can be used in the treatment of pathologies associated with PTPase activity. Formula (I) Compounds of formula (I), particularly those of formula (I), inhibit PTP-1B and TC PTP and can therefore be used in the treatment of pathologies associated with PTPase activity. The compounds of the present invention can also be used for the inhibition of other enzymes having a phosphotyrosine binding region such as an SH2 domain. Therefore, the compound of formula (I) is insulin resistance related to obesity, glucose intolerance, diabetes mellitus, hypertension, ischemic disease, hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis A number of medical conditions with type 2 diabetes, including irritable bowel syndrome, pancreatitis, lipocytoma, carcinoma, dyslipidemia, other disorders with insulin resistance, cancer, osteoporosis, neurodegenerative and infectious diseases, And can be used to treat or prevent diseases related to inflammation and the immune system. [Selection figure] None |